Recent news highlights include CV Sciences' plans to acquire Extract Labs to support growth and a reported 10% decline in sales in 2025. Other cannabis industry news provides context but is not directly related to CV Sciences.

• CV Sciences announced plans to acquire Extract Labs as part of its growth strategy [N1].
• The company reported a 10% decline in sales as of August 2025 [N2].
• Other cannabis industry developments include reports on PharmaCann default, biopharma company HMNC Brain Health, Organigram's acquisition of Motif Labs, and quarterly earnings reports from cannabis firms, providing broader market context [N3][N4][N5][N6].

CV Sciences benefits from a leading position in the hemp extract market with its +PlusCBD™ brand, supported by scientific validation and regulatory milestones such as GRAS status. The company's expansion into plant-based foods and cannabinoid-free supplements diversifies its revenue streams. Strategic acquisitions like Cultured Foods and Elevated Softgels enhance manufacturing capabilities and product breadth. The company’s broad distribution network across retail and e-commerce channels supports consumer access and brand visibility. Ongoing product innovation and cost management efforts may improve operational efficiency and market responsiveness.

CV Sciences faces significant regulatory uncertainty due to evolving federal and state laws governing hemp-derived products, including stricter THC limits effective November 2026 that could restrict product offerings. The company operates in a highly competitive and fragmented market with pressure from both licensed and illicit operators. Financially, CV Sciences reported a net loss and negative operating cash flow in 2025, with a modest cash position and working capital constraints. Manufacturing constraints have caused temporary product shortages. The company’s drug development program is dormant due to capital limitations, and its ability to raise additional capital remains uncertain, posing risks to ongoing operations and growth initiatives.

CV Sciences' moat is anchored in its established +PlusCBD™ brand, recognized as the top-selling hemp extract brand in the natural products market, supported by scientific research and GRAS status. The company's diversified product portfolio across hemp-based and plant-based food categories, combined with its multi-channel distribution network including thousands of retail locations and e-commerce, provides market reach and consumer trust. Strategic acquisitions have enhanced manufacturing capabilities and product offerings, while robust quality control and supplier relationships support product consistency. However, the company operates in a highly competitive and fragmented market with regulatory uncertainties that may challenge sustained differentiation.

• Regulatory Risk: The company operates in a complex and evolving regulatory environment with federal and state laws impacting hemp-derived products. Changes effective November 2026 impose stricter THC limits and product restrictions, potentially affecting product availability and sales.
• Competitive Market: CV Sciences faces intense competition from numerous licensed and illicit market operators in the CBD and plant-based food sectors, which may impact market share and pricing.
• Financial and Liquidity Risk: The company reported a net loss and negative cash flow from operations in 2025, with limited cash reserves and working capital. Dependence on additional capital raises and financing agreements introduces uncertainty to ongoing operations.
• Manufacturing Constraints: Temporary out-of-stock situations due to manufacturing constraints may affect near-term revenue and customer fulfillment.
• Product Development and Innovation: The drug development program is dormant due to capital constraints, limiting potential future revenue streams from novel therapeutics.

• CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods, with a focus on hemp extracts and natural ingredients.
• The company sells products through B2B and B2C channels, including approximately 2,500 brick and mortar stores and e-commerce platforms.
• Its flagship brand, +PlusCBD™, is the top-selling hemp extract brand in the natural products market in the U.S., supported by human clinical research and GRAS status.
• CV Sciences owns four main brands: +PlusCBD™, +PlusHLTH™ (cannabinoid-free supplements launched in 2024), Cultured Foods™ (European plant-based protein products acquired in 2023), and Lunar Fox™ (U.S. plant-based products launched in 2025).
• The company acquired Elevated Softgels, LLC in 2024, a manufacturer of encapsulated softgels and tinctures for the supplement industry, with flexible production runs.
• CV Sciences has a dormant drug development program for CBD-based therapeutics, including a patented product candidate CVSI-007 for smokeless tobacco addiction, but further development is curtailed due to capital constraints.
• The company operates manufacturing and distribution facilities in San Diego, California; Grand Junction, Colorado; and Warsaw, Poland.
• As of December 31, 2025, CV Sciences had 44 employees, with most in the U.S. and some in Poland.
• For the year ended December 31, 2025, the company sold more than 50 products across its brands and launched 39 new products since January 1, 2023, which accounted for 39% of net revenue.
• Product sales for 2025 were $13.8 million, down 12.2% from $15.7 million in 2024, with a gross margin of 49.0% compared to 45.6% in 2024.
• Sales are split between B2B (56.1%) and B2C (43.9%) channels.
• The company faces intense competition in the CBD consumer product market from both licensed and illicit operators, as well as in the European plant-based food market, which is fragmented and competitive.
• CV Sciences maintains robust quality assurance and testing protocols, including third-party ISO accredited lab testing for raw materials and finished products.
• The company sources hemp raw materials globally, including Europe and the U.S., maintaining relationships with growers to support anticipated revenue growth.
• CV Sciences is subject to complex and evolving federal and state regulations regarding hemp-derived CBD products, including recent changes effective November 12, 2026, that impose stricter THC limits and product restrictions.
• The company monitors regulatory developments closely and is affected by the patchwork of state laws and federal oversight, including FDA regulations on CBD in food and supplements.
• CV Sciences' financials for the year ended December 31, 2025, show a net loss of $958,000 and basic and diluted EPS of -$0.01.
• As of December 31, 2025, the company had $611,000 in cash and cash equivalents, current assets of $5.13 million, current liabilities of $5.0 million, resulting in a current ratio of 1.03 and a cash ratio of 0.12.
• The company generated negative cash flow from operations of $0.4 million in 2025 and had an accumulated deficit of $87.9 million as of year-end.
• CV Sciences has secured promissory notes and financing agreements with institutional investors, including amendments that provide conversion features and adjusted repayment terms.
• The company has been making strategic cost reductions, including employee headcount and vendor spending, to improve financial performance.
• CV Sciences intends to continue building its consumer products platform, evaluating mergers, acquisitions, and sales opportunities to optimize value.
• The company sells its plant-based food products primarily in Europe through distributors and its hemp-based products primarily in North America through retail channels.
• The company experienced manufacturing constraints causing temporary out-of-stock situations for some key products, working to normalize inventory levels in 2026.
• CV Sciences' three largest customers accounted for approximately 8-9% of total sales, indicating limited customer concentration risk.